KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Acadia Pharmaceuticals (ACAD) Enterprise Value (2016 - 2025)

Historic Enterprise Value for Acadia Pharmaceuticals (ACAD) over the last 17 years, with Q3 2025 value amounting to -$847.0 million.

  • Acadia Pharmaceuticals' Enterprise Value fell 4982.74% to -$847.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$847.0 million, marking a year-over-year decrease of 4982.74%. This contributed to the annual value of -$756.0 million for FY2024, which is 7226.09% down from last year.
  • Latest data reveals that Acadia Pharmaceuticals reported Enterprise Value of -$847.0 million as of Q3 2025, which was down 4982.74% from -$762.0 million recorded in Q2 2025.
  • Acadia Pharmaceuticals' 5-year Enterprise Value high stood at -$345.9 million for Q3 2023, and its period low was -$847.0 million during Q3 2025.
  • Moreover, its 5-year median value for Enterprise Value was -$500.9 million (2024), whereas its average is -$530.4 million.
  • Its Enterprise Value has fluctuated over the past 5 years, first skyrocketed by 2281.04% in 2022, then plummeted by 7226.09% in 2024.
  • Acadia Pharmaceuticals' Enterprise Value (Quarter) stood at -$520.7 million in 2021, then increased by 19.95% to -$416.8 million in 2022, then dropped by 5.29% to -$438.9 million in 2023, then tumbled by 72.26% to -$756.0 million in 2024, then decreased by 12.04% to -$847.0 million in 2025.
  • Its Enterprise Value was -$847.0 million in Q3 2025, compared to -$762.0 million in Q2 2025 and -$681.6 million in Q1 2025.